Skip to content
Levaquin, Quinsair(levofloxacin)
Iquix, Levaquin, Quinsair, Quixin (levofloxacin) is a small molecule pharmaceutical. Levofloxacin was first approved as Levaquin on 1996-12-20. It is used to treat bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bronchitis amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
eye diseasesD005128
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levofloxacin
Tradename
Company
Number
Date
Products
LEVAQUINJohnson & JohnsonN-020634 DISCN1996-12-20
3 products, RLD
LEVAQUINJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERJohnson & JohnsonN-020635 DISCN1996-12-20
2 products, RLD
LEVAQUINJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUINJohnson & JohnsonN-021721 DISCN2004-10-21
1 products, RLD
QUIXINSantenN-021199 DISCN2000-08-18
1 products, RLD
IQUIXSantenN-021571 DISCN2004-03-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
levaquinANDA2016-05-26
levofloxacinANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial eye infections—D015818—
bacterial infections—D001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
bronchitis—D001991J40
chlamydia infectionsEFO_0007205D002690A74.9
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
klebsiella infectionsEFO_1001353D007710—
legionnaires' diseaseEFO_0007343D007877A48.1
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD10: Lansoprazole, amoxicillin and levofloxacin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA12: Levofloxacin
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA05: Levofloxacin and ornidazole
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE05: Levofloxacin
HCPCS
Code
Description
J1956
Injection, levofloxacin, 250 mg
Clinical
Clinical Trials
263 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——1022739
Urinary tract infectionsD014552EFO_0003103N39.0—286—16
Healthy volunteers/patients—61—3111
PneumoniaD011014EFO_0003106J18—281—10
CataractD002386EFO_0001059H26.93114—9
Multidrug-resistant tuberculosisD018088EFO_0007381—451—9
EndophthalmitisD00987733—115
Pulmonary tuberculosisD014397EFO_1000049A15—122—4
Pelvic inflammatory diseaseD000292EFO_1001388N70-N77——22—4
Otitis mediaD010033EFO_0004992H66.9——31—4
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16—25——7
TuberculosisD014376EFO_0000774A15-A19223—16
Hiv infectionsD015658EFO_0000764B202—1—25
Chronic bronchitisD029481J42—15——5
ProstatitisD011472EFO_0003830N41—14——5
Diabetic footD017719EFO_1001459—32——5
Bacterial infectionsD001424A491—3——4
NeoplasmsD009369C80—23——4
Cystic fibrosisD003550EFO_0000390E842—2——4
Maxillary sinusitisD015523EFO_0007361J32.0——3——3
Show 45 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyopiaD009216H52.111——12
SarcoidosisD012507EFO_0000690D80-D89—1———1
Non-hodgkin lymphomaD008228C85.9—1———1
PterygiumD011625H11.011———1
Corneal diseasesD003316H18.911———1
HyperopiaD006956H52.011———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary sarcoidosisD017565DOID_13406D86.01————1
Retinal diseasesD012164HP_0000479H35.91————1
Hearing lossD034381EFO_0004238H91.91————1
Escherichia coli infectionsD004927EFO_1001318B96.201————1
Short bowel syndromeD0127781————1
PharmacokineticsD0105991————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.9————22
MicrobiotaD064307————11
Chemical and drug induced liver injuryD056486————11
Refractive errorsD012030EFO_0003908H52.7————11
TherapeuticsD013812————11
Helicobacter pyloriD016480NCBITaxon_210B96.81————11
RadiotherapyD011878————11
Drug-related side effects and adverse reactionsD064420T88.7————11
Drug monitoringD016903————11
EpistaxisD004844EFO_0003895R04.0————11
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVOFLOXACIN
INNlevofloxacin
Description
Levofloxacin is an optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase. It has a role as a DNA synthesis inhibitor, an antibacterial drug, a topoisomerase IV inhibitor and an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor. It is a quinolone antibiotic, a fluoroquinolone antibiotic and a 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid. It is an enantiomer of a dextrofloxacin.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Identifiers
PDB—
CAS-ID100986-85-4
RxCUI1546009
ChEMBL IDCHEMBL33
ChEBI ID63598
PubChem CID149096
DrugBankDB01137
UNII IDRIX4E89Y14 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Quinsair - Horizon Therapeutics Public
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 34,614 documents
View more details
Safety
Black-box Warning
Black-box warning for: Levofloxacin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
56,462 adverse events reported
View more details